Skip to main content
. 2019 Mar 12;10(21):2030–2040. doi: 10.18632/oncotarget.26771

Figure 1. Representative images of immunohistochemistry in DLBCL.

Figure 1

(A) High PD-1 expression in lymphoma cells. (B) Negative PD-1 expression in tumor cells, positive in TILs. (C) High PD-L1 expression in lymphoma cells. (D) Negative PD-L1 expression in tumor cells, positive in TILs. (E) High TIM-3 expression in lymphoma cells. (F) Negative TIM-3 expression in tumor cells, positive in TILs. (G) High LAG-3 expression in lymphoma cells. (H) Negative LAG-3 expression in tumor cells, positive in TILs.

HHS Vulnerability Disclosure